Health & Medicine
Novel Kidney Drug INM004 Enters Final Trial for Life-Threatening HUS
Argentine biotech Inmunova has initiated a Phase 3 clinical trial for INM004, a novel drug designed to neutralize the Shiga toxin responsible for Haemolytic Uraemic Syndrome (HUS). This investigational therapy aims to be the first specific treatment for the severe kidney disorder, potentially preventing irreversible organ damage.
Marcus Cole·October 4, 2026
